Stelara
E50227
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Stelara canonical | 4 |
How this entity was disambiguated
This entity first appeared as the object of triple T391437 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Stelara Context triple: [Johnson & Johnson, notableProduct, Stelara]
-
A.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Stelara Target entity description: Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
A.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
E.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ prescription drug ⓘ |
| hasATCCode | L04AC05 ⓘ |
| hasCommonSideEffect |
fatigue
ⓘ
headache ⓘ injection site reactions ⓘ upper respiratory infections ⓘ |
| hasDosingFrequency | every 8 weeks (maintenance, common regimen) ⓘ |
| hasDrugClass | interleukin inhibitor ⓘ |
| hasGenericName | ustekinumab ⓘ |
| hasInitialDosing |
weight-based intravenous induction for Crohn’s disease
ⓘ
weight-based intravenous induction for ulcerative colitis ⓘ |
| hasMaintenanceDosing | subcutaneous injection ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasPediatricIndicationFor |
plaque psoriasis
ⓘ
psoriatic arthritis ⓘ |
| hasRouteOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| hasSeriousRisk |
hypersensitivity reactions
ⓘ
malignancies ⓘ serious infections ⓘ |
| hasTargetDiseaseArea |
dermatology
ⓘ
gastroenterology ⓘ rheumatology ⓘ |
| isAdministered | parenterally ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isApprovedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| isContraindicatedIn | patients with clinically significant hypersensitivity to ustekinumab ⓘ |
| isIndicatedIn |
adults
ⓘ
pediatric patients ⓘ |
| isManufacturedBy | Janssen Biotech ⓘ |
| isMarketedBy |
Janssen
ⓘ
linked to:
Janssen Pharmaceuticals
|
| isUsedFor |
Crohn’s disease
ⓘ
active psoriatic arthritis ⓘ moderate to severe plaque psoriasis ⓘ moderately to severely active Crohn’s disease ⓘ moderately to severely active ulcerative colitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ ulcerative colitis ⓘ |
| mechanismOfAction |
binds to p40 subunit of IL-12 and IL-23
ⓘ
blocks IL-12 and IL-23 mediated signaling ⓘ |
| reduces | inflammation ⓘ |
| regulates | immune system response ⓘ |
| requiresMonitoringFor | signs of infection ⓘ |
| targets |
interleukin-12
ⓘ
interleukin-23 ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Stelara Description of subject: Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.